160 related articles for article (PubMed ID: 16253597)
1. Experience with statin use in patients with chronic hepatitis C infection.
Gibson K; Rindone JP
Am J Cardiol; 2005 Nov; 96(9):1278-9. PubMed ID: 16253597
[TBL] [Abstract][Full Text] [Related]
2. Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients.
Huang CY; Wu TC; Lin WT; Leu HB; Lin CP; Lin SJ; Chen JW
Eur J Clin Invest; 2006 Feb; 36(2):76-84. PubMed ID: 16436088
[TBL] [Abstract][Full Text] [Related]
3. A statin in every medicine cabinet?
Walsh MN
Health News; 2002 Sep; 8(9):3. PubMed ID: 12229899
[No Abstract] [Full Text] [Related]
4. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
5. Successful conversion of patients with hypercholesterolemia from a brand name to a generic cholesterol-lowering drug.
Cheetham TC; Chan J; Benson V; Richmond C; Levin E; Campen D
Am J Manag Care; 2005 Sep; 11(9):546-52. PubMed ID: 16159044
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
Strony J; Hoffman R; Hanson M; Veltri E
Clin Ther; 2008 Dec; 30(12):2280-97. PubMed ID: 19167588
[TBL] [Abstract][Full Text] [Related]
7. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
[TBL] [Abstract][Full Text] [Related]
8. Transportability and reproducibility of the AST/ALT ratio in chronic hepatitis C patients.
Giannini E; Risso D; Testa R
Am J Gastroenterol; 2001 Mar; 96(3):918-9. PubMed ID: 11280581
[No Abstract] [Full Text] [Related]
9. How common is rhabdomyolysis in patients receiving lipid-lowering therapy?
Phillips PS
Nat Clin Pract Cardiovasc Med; 2005 Mar; 2(3):130-1. PubMed ID: 16265453
[No Abstract] [Full Text] [Related]
10. [Aspartate aminotransferase (AST) more than alanine aminotransferase (ALT) levels predict the progression of liver fibrosis in chronic HCV infection].
Stránský J; Ryzlová M; Striteský J; Horák J
Vnitr Lek; 2002 Oct; 48(10):924-8. PubMed ID: 16737138
[TBL] [Abstract][Full Text] [Related]
11. A study of the effect of splenectomy on hepatic functional reserve and structural damage in patients with chronic hepatitis C virus infection by non-invasive serum markers. A prospective study.
Elsebae MM; Abu-Zekri NB
Int J Surg; 2008 Oct; 6(5):362-6. PubMed ID: 18662898
[TBL] [Abstract][Full Text] [Related]
12. Prevalence, aetiology and associated co-morbidities of elevated aminotransferases in a german cohort of orthopaedic surgery patients.
Lobstein S; Kaiser T; Liebert U; Wojan M; Leichtle A; Mössner J; Wiegand J; Tillmann HL
Z Gastroenterol; 2008 May; 46(5):415-20. PubMed ID: 18461515
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of the AST/ALT ratio in chronic hepatitis C.
Imperiale TF; Born LJ
Am J Gastroenterol; 2001 Mar; 96(3):919-20. PubMed ID: 11280582
[No Abstract] [Full Text] [Related]
14. Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C.
Hsieh MY; Dai CY; Lee LP; Huang JF; Tsai WC; Hou NJ; Lin ZY; Chen SC; Wang LY; Chang WY; Chuang WL; Yu ML
J Clin Pathol; 2008 Mar; 61(3):333-7. PubMed ID: 17545561
[TBL] [Abstract][Full Text] [Related]
15. Coadministration of valsartan 160 and 320 mg and simvastatin 20 and 40 mg in patients with hypertension and hypercholesterolemia: a multicenter, 12-week, double-blind, double-dummy, parallel-group superiority study.
Rump LC; Baranova E; Okopien B; Weisskopf M; Kandra A; Ferber P
Clin Ther; 2008 Oct; 30(10):1782-93. PubMed ID: 19014834
[TBL] [Abstract][Full Text] [Related]
16. Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis.
Papatheodoridis GV; Chrysanthos N; Savvas S; Sevastianos V; Kafiri G; Petraki K; Manesis EK
J Viral Hepat; 2006 May; 13(5):303-10. PubMed ID: 16637860
[TBL] [Abstract][Full Text] [Related]
17. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study.
Reckless JP; Henry P; Pomykaj T; Lim ST; Massaad R; Vandormael K; Johnson-Levonas AO; Lis K; Brudi P; Allen C
Int J Clin Pract; 2008 Apr; 62(4):539-54. PubMed ID: 18266852
[TBL] [Abstract][Full Text] [Related]
18. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.
Pearson T; Ballantyne C; Sisk C; Shah A; Veltri E; Maccubbin D
Am J Cardiol; 2007 Jun; 99(12):1706-1713. PubMed ID: 17560879
[TBL] [Abstract][Full Text] [Related]
19. Goals of statin conversion program.
Resch NK
Am J Health Syst Pharm; 2002 Feb; 59(4):380-1. PubMed ID: 11885406
[No Abstract] [Full Text] [Related]
20. Petechial eruptions due to simvastatin in a patient with diabetes mellitus and liver cirrhosis.
Horiuchi Y; Maruoka H
J Dermatol; 1997 Aug; 24(8):549-51. PubMed ID: 9301152
[No Abstract] [Full Text] [Related]
[Next] [New Search]
